The cellular damage caused by chronic IRI can culminate in various forms of cell death, including apoptosis, autophagy, necrosis, and necroptosis [3]
Eli Lilly and Company Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Most therapies are weekly, some bi-weekly and maintenance therapies are often monthly
The symptoms are wide-ranging and often debilitating: flushing, hives, abdominal pain, brain fog, heart palpitations, and severe fatigue
Statements Data availability statement The mass spectrometry proteomics and phosphoproteomics data generated in this study are in the process of being deposited to the ProteomeXchange Consortium via the PRIDE partner repository
The 16S rRNA gene sequences were downloaded from Entrez at NCBI using accession numbers retrieved from peer-reviewed publications